SCHEDULE: T. Rowe Price Discloses 0.1% Stake in Avidity Biosciences

T. Rowe Price Associates, Inc. has filed an Amendment No. 8 to Schedule 13G, reporting a 0.1% beneficial ownership in Avidity Biosciences Inc.

Summary

• T. Rowe Price Associates, Inc. reported beneficial ownership of 142,888 shares of Avidity Biosciences Inc. common stock.
• This ownership represents 0.1% of the class of securities.
• T. Rowe Price holds sole voting power over 140,624 shares and sole dispositive power over 142,888 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of a very small, passive institutional ownership stake and provides no new operational or financial information about the issuer.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• T. Rowe Price Associates, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of institutional ownership, common for investment advisers like T. Rowe Price. A 0.1% stake is a very minor position, indicating a passive investment rather than a strategic move to influence the company.

Stakeholder Impact

• The reported 0.1% beneficial ownership by T. Rowe Price is a very small stake and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors of Avidity Biosciences Inc.

Key Dates

Keywords

Avidity Biosciences, T. Rowe Price, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology